The relationship between type 2 diabetes, NAFLD, and cardiovascular risk
C Caussy, A Aubin, R Loomba - Current diabetes reports, 2021 - Springer
Abstract Purpose of Review Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
mellitus (T2DM) are strongly associated. Both also associate with an increased risk of …
mellitus (T2DM) are strongly associated. Both also associate with an increased risk of …
Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
AJ Scheen - Circulation research, 2018 - Am Heart Assoc
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
Importance Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2
(SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events …
(SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events …
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
R Puckrin, MP Saltiel, P Reynier, L Azoulay, OHY Yu… - Acta …, 2018 - Springer
Aims There is concern about the infection-related safety profile of sodium–glucose co-
transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on …
transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on …
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …
Medical therapy for heart failure caused by ischemic heart disease
IY Elgendy, D Mahtta, CJ Pepine - Circulation research, 2019 - Am Heart Assoc
Patients with heart failure (HF) syndromes have been categorized as those with reduced
ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types …
ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types …
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis
Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on
cardiovascular outcomes have not been well established. We pooled evidence from all …
cardiovascular outcomes have not been well established. We pooled evidence from all …
Mortality and cardiovascular disease in type 1 and type 2 diabetes
T Htay, K Soe, A Lopez-Perez, AHA Doan… - Current cardiology …, 2019 - Springer
Abstract Purpose of Review The aims of this review are to summarize recent data on
mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine …
mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine …
[HTML][HTML] Complementary and alternative medicine for the treatment of diabetes and associated complications: A review on therapeutic role of polyphenols
Background: Diabetes is one of the most challenging health problems in 21st century. It is a
group of endocrine-metabolic disorder characterized by high glucose level (hyperglycemia) …
group of endocrine-metabolic disorder characterized by high glucose level (hyperglycemia) …
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Background Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …